Knight Sara J, Latini David M
San Francisco VA Medical Center, University of California at San Francisco, San Francisco, CA, USA.
Cancer J. 2009 Jan-Feb;15(1):41-4. doi: 10.1097/PPO.0b013e31819764cc.
Prostate cancer treatment decision making requires complex trade-offs among treatment outcomes, and sexual function is a central consideration for most men. Although sexual function is included in prostate cancer decision models, survival and fear of recurrence and cancer progression weigh more heavily in these decisions for many men than concerns about treatment impact on sexuality. In this article, we discuss the importance of sexuality in men's treatment decisions for prostate cancer. We focus on men's preferences for maintaining sexual function and their needs for information about the risk of sexual side effects with prostate cancer treatment. Our review suggests that among men diagnosed with prostate cancer sexual function is less important to men than concerns about survival, but is more highly valued than other side effects and treatment characteristics. However, there is evidence that concerns about sexuality are not in proportion with the associated risk for sexual problems with prostate cancer treatment and men acknowledge unmet needs for information about sexuality in making prostate cancer treatment decisions.
前列腺癌治疗决策需要在治疗结果之间进行复杂的权衡,而性功能是大多数男性的核心考量因素。虽然性功能被纳入了前列腺癌决策模型,但对于许多男性来说,在这些决策中,生存以及对复发和癌症进展的恐惧比治疗对性功能的影响更为重要。在本文中,我们讨论了性功能在男性前列腺癌治疗决策中的重要性。我们关注男性对于维持性功能的偏好以及他们对前列腺癌治疗后性功能副作用风险信息的需求。我们的综述表明,在被诊断患有前列腺癌的男性中,性功能对他们来说不如对生存的担忧重要,但比其他副作用和治疗特征更受重视。然而,有证据表明,对性功能的担忧与前列腺癌治疗相关的性功能问题风险不成比例,并且男性承认在做出前列腺癌治疗决策时对性功能信息的需求未得到满足。